Ro60-0213 (Org 35032) is a drug developed by Hoffmann–La Roche, which acts as a potent and selective agonist for the 5-HT2C serotonin receptor, with more than 100x selectivity over other closely related serotonin receptor subtypes, and little or no affinity at other receptors.

It was developed as a potential antidepressant,[1] but was discontinued from clinical development at an early stage due to toxicity concerns.

[2] However the high selectivity of Ro60-0213 for 5-HT2C makes it of continued interest for research into serotonin receptors.

[3] This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.